All News

CV,risk,MI,heart,cardiac

Heart Failure in RA: Inflammation Matters

d MedPage Today

Patients with rheumatoid arthritis (RA) who had high levels of inflammation at baseline were at increased risk for later heart failure, a large cohort study found.

Read Article
COVID Test Antibody

Is It OK to Continue TNF Inhibitors with COVID-19 Infection?

d Jack Cush, MD

Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis

d Jack Cush, MD

B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.

Read Article
SI,sacroiliitis,erosion

TICOSPA - Does Treat to Target Work in Spondyloarthritis?

d Jack Cush, MD

Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).

Read Article
JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM

Links:

Dr. John Cush RheumNow ( View Tweet)

Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d. (Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Dr. Robert Chao ( @doctorRBC ) reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented at the virtual EULAR 2021 meeting. https://t.co/7FmZ4BzHwp

Links:

Dr. John Cush RheumNow ( View Tweet)

B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies. https://t.co/pMXWmuJw5Y https://t.co/1raYa1vLtK

Links:

Dr. John Cush RheumNow ( View Tweet)
TICOSPA - Does Treat to Target Work in Spondyloarthritis? https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J

Links:

Dr. John Cush RheumNow ( View Tweet)
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download wherever you get your podcasts! https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU

Links:

Dr. John Cush RheumNow ( View Tweet)

Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly https://t.co/LpEOgbcfpP

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3

Links:

Dr. John Cush RheumNow ( View Tweet)

Are You a High or Low Glucocorticoid Prescriber? https://t.co/QbJzlrVMiV https://t.co/dZgJPKjisx

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC. Read more on #RheumNow https://t.co/Q422Sl5Csj

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download. https://t.co/Y6Pqko1tYm https://t.co/2IvMIfPBkr

Links:

Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/1pnXJkoCOn

Links:

Dr. John Cush RheumNow ( View Tweet)
×